Evaluation of Tacrolimus in Ulcerative Colitis: Factors Influencing Remission and Maintenance
Overview
This retrospective study analyzed tacrolimus (TAC) therapy in ulcerative colitis (UC) patients, focusing on remission induction rates, maintenance of remission, and adverse events. The study found a remission induction rate of approximately 79%, with maintenance rates varying by therapy type, and identified clinical and endoscopic factors associated with successful outcomes.
Background
Ulcerative colitis is a chronic inflammatory bowel disease with increasing global incidence. Tacrolimus, a calcineurin inhibitor, remains a key treatment for intractable UC, often used alongside azathioprine (AZA) or biologic agents for maintenance therapy. Despite TAC's superior short-term remission induction compared to infliximab, relapse rates remain high, necessitating evaluation of factors influencing remission and maintenance. AZA is effective for maintenance but can cause serious adverse events, some predictable by NUDT15 gene testing.
Data Highlights
Phase
Population
Outcome
Key Findings
Phase 1
136 UC patients receiving TAC
Remission induction rate
79% (108/136) achieved remission (LCAI ≤4 at 4 weeks)
Phase 2
99 patients in remission
Overall remission maintenance at 52 weeks
Approximately 52% maintained remission
Phase 3
78 patients on single maintenance therapy
Remission maintenance by drug
AZA (n=58), TAC (n=12), Biologics (n=8); maintenance rates varied by drug
Remission induction with TAC was achieved in 79% of UC patients within 4 weeks.
Factors associated with remission included lower baseline LCAI scores and favorable endoscopic scores (Mayo and UCEIS).
At 52 weeks, about half of patients maintained remission; maintenance rates differed by maintenance therapy drug.
AZA maintenance therapy was effective but carried risks of adverse events, some predictable by NUDT15 gene testing.
Patients intolerant to AZA or with relapse may require switching to biologic agents for maintenance.
Monitoring TAC trough levels and adjusting doses were critical for both induction and maintenance phases.
Clinical Implications
Tacrolimus is effective for inducing remission in UC, with a high initial response rate. Careful patient selection and monitoring of clinical and endoscopic parameters can optimize remission induction. For maintenance, AZA remains a standard option but requires vigilance for adverse events, with genetic testing aiding risk stratification. Biologic agents serve as alternatives for patients intolerant to AZA or experiencing relapse.
Conclusion
Tacrolimus is a valuable therapy for inducing remission in ulcerative colitis, with maintenance success influenced by the choice of maintenance drug and patient-specific factors. Personalized treatment strategies, including genetic testing and therapeutic drug monitoring, can improve long-term outcomes.
References
Global UC incidence trends [1]
Newer drugs and treatment options for UC [2]
Tacrolimus and infliximab as mainstays for severe UC [3]
Short-term outcomes: TAC vs infliximab [4]
Colorectal resection rates post-TAC remission [5]
Azathioprine in UC maintenance therapy [6]
Effectiveness of AZA [7]
AZA adverse events [8]
NUDT15 gene and AZA adverse events [9]
Lichtiger Colitis Activity Index and endoscopic scores [10,11,12]
